News Releases

November 20, 2020
Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference
CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will participate in a virtual
November 18, 2020
Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020
Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and 20% ORR, including a complete response, in a heavily pre-treated GIST population; 27% of patients remain on therapy out 27-34 months   Combination showed no dose limiting toxicities
November 12, 2020
Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference
CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate
November 9, 2020
Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Andrew Robbins appointed President, CEO and Director   Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients selected for oral presentation at Connective Tissue Oncology Society (CTOS) 2020 meeting   Ended quarter with $129.4 million in cash, including proceeds from $104.4M Series
November 5, 2020
Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 5, 2020 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will virtually present a
October 26, 2020
Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer
Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma CAMBRIDGE, Mass. , Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences , Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing
October 5, 2020
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients   Company on track to advance CGT9486 into Systemic Mastocytosis patients in 1H21   Abstract selected for oral presentation at CTOS 2020   New data from the Phase 1/2 clinical trial of
August 31, 2020
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO
Transaction focused on the BOXR technology including lead program BOXR1030   Company fully focused on the development of small molecule precision kinase inhibitors to treat a range of genetically driven diseases   Peter Harwin appointed as Board Chair CAMBRIDGE, Mass. , Aug.
August 11, 2020
Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
Completed acquisition of Kiq, including lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor   Company positioned to advance best-in-class precision kinase inhibitors   Advancing clinical trials in Systemic Mastocytosis and Gastrointestinal Stromal Tumors ('GIST')
July 6, 2020
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor   Company positioned to advance best-in-class precision kinase inhibitors   Proceeds of $104.4 million to be used to advance clinical testing in mastocytosis and GIST   Conference call today at
Displaying 1 - 10 of 15
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.